{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:24:33Z","timestamp":1790771073641,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004561","name":"Ministry of Science and Higher Education of the Republic of Kazakhstan","doi-asserted-by":"publisher","award":["AP13068072"],"award-info":[{"award-number":["AP13068072"]}],"id":[{"id":"10.13039\/501100004561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"LEO Foundation","doi-asserted-by":"publisher","award":["LF-OC-23-001288"],"award-info":[{"award-number":["LF-OC-23-001288"]}],"id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.molmed.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T12:07:44Z","timestamp":1714824464000},"page":"844-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Vitiligo: advances in pathophysiology research and treatment development"],"prefix":"10.1016","volume":"30","author":[{"given":"Zhussipbek","family":"Mukhatayev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-4007","authenticated-orcid":false,"given":"I. Caroline","family":"Le Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.04.009_bb0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.711080","article-title":"Editorial: Immunology of vitiligo","volume":"12","author":"Seneschal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0015","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227909","article-title":"The relationship between stress and vitiligo: evaluating perceived stress and electronic medical record data","volume":"15","author":"Henning","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.04.009_bb0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70i is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/exd.12183","article-title":"A central role for inducible heat-shock protein 70 in autoimmune vitiligo","volume":"22","author":"Mosenson","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.04.009_bb0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/pcmr.12208","article-title":"Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress","volume":"27","author":"Mosenson","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0050","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2008.45","article-title":"HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo","volume":"128","author":"Denman","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine","volume":"138","author":"Henning","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0060","first-page":"1219","article-title":"Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance","volume":"148","author":"Le Poole","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2024.04.009_bb0075","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.04.009_bb0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0090","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0095","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0100","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4(+) \/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0105","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate Treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/pcmr.12284","article-title":"Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation","volume":"27","author":"Eby","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0115","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0120","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.04.009_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by Tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0130","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0135","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41590-019-0404-3","article-title":"Tissue patrol by resident memory CD8+ T cells in human skin","volume":"20","author":"Dijkgraaf","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2024.04.009_bb0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.04.009_bb0155","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood-2003-01-0183","article-title":"IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro","volume":"102","author":"Alves","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2024.04.009_bb0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/09629359891126","article-title":"Topical glucocorticoids and the skin--mechanisms of action: an update","volume":"7","author":"Ahluwalia","year":"1998","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.molmed.2024.04.009_bb0165","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thoraxjnl-2016-209397","article-title":"Corticosteroids and infliximab impair the performance of interferon-\u03b3 release assays used for diagnosis of latent tuberculosis","volume":"72","author":"Alexander","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.molmed.2024.04.009_bb0170","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1073\/pnas.96.21.11776","article-title":"Glucocorticoid receptor inhibits transforming growth factor-\u03b2 signaling by directly targeting the transcriptional activation function of Smad3","volume":"96","author":"Song","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2024.04.009_bb0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.immuni.2020.10.022","article-title":"Competition for active TGF\u03b2 cytokine allows for selective retention of antigen-specific tissue-resident memory T cells in the epidermal niche","volume":"54","author":"Hirai","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2024.04.009_bb0180","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bjd.19592","article-title":"Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial*","volume":"184","author":"Thomas","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0185","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force\u2014Part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0190","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1073\/pnas.89.9.3686","article-title":"Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A","volume":"89","author":"Fruman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2024.04.009_bb0195","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00007890-200007270-00017","article-title":"Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations","volume":"70","author":"Kung","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2024.04.009_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/561018","article-title":"Mechanisms of action of topical corticosteroids in psoriasis","volume":"2012","author":"Uva","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0205","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2133.2011.10351.x","article-title":"A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71% vs. clobetasol propionate 0\u00b705% in childhood vitiligo","volume":"165","author":"Ho","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0210","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1346-8138.2010.00929.x","article-title":"Recent onset vitiligo treated with systemic corticosteroid and topical tacrolimus: need for early treatment in vitiligo","volume":"37","author":"Lee","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0225","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.04.009_bb0230","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.molmed.2024.04.009_bb0235","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","article-title":"Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo","volume":"142","author":"Pandya","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0240","first-page":"882","article-title":"Phototherapy: theory and practice","volume":"21","author":"Kurz","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.molmed.2024.04.009_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/1011-1344(92)85080-E","article-title":"The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD","volume":"14","author":"Pathak","year":"1992","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0190-9622(92)70021-7","article-title":"PUVA and skin cancer. A historical cohort study on 492 patients","volume":"26","author":"Chuang","year":"1992","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1468-3083.2006.01413.x","article-title":"Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo","volume":"20","author":"Parsad","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0260","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0265","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/jid.2010.5","article-title":"Regulation of human skin pigmentation in situ by repetitive UV exposure: molecular characterization of responses to UVA and\/or UVB","volume":"130","author":"Choi","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.0022-202X.2004.23551.x","article-title":"Single UVB overexposure stimulates melanocyte proliferation in murine skin, in contrast to fractionated or UVA-1 exposure","volume":"124","author":"van Schanke","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0275","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/exd.12344","article-title":"Beyond vitiligo guidelines: combined stratified\/personalized approaches for the vitiligo patient","volume":"23","author":"Anbar","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0280","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1525-1470.2011.01683.x","article-title":"Narrowband ultraviolet B phototherapy in childhood vitiligo: evaluation of results in 28 patients","volume":"29","author":"Percivalle","year":"2012","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0285","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15058","article-title":"Is targeted UVB as effective as excimer light phototherapy in treatment of vitiligo?","volume":"34","author":"Tabassum","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.molmed.2024.04.009_bb0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2015.04.008","article-title":"Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients","volume":"73","author":"Bae","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0295","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clindermatol.2016.05.009","article-title":"Phototherapy: the vitiligo management pillar","volume":"34","author":"Esmat","year":"2016","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0300","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clindermatol.2016.05.010","article-title":"Portable home phototherapy for vitiligo","volume":"34","author":"Eleftheriadou","year":"2016","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bjd.17150","article-title":"Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo","volume":"180","author":"Tovar-Garza","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0310","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000433424","article-title":"A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo","volume":"231","author":"Singh","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.molmed.2024.04.009_bb0315","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaad.2019.03.025","article-title":"A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive nonsegmental vitiligo","volume":"85","author":"Patra","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0320","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0325","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0330","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.det.2016.11.012","article-title":"The role of diet and supplements in vitiligo management","volume":"35","author":"Grimes","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.molmed.2024.04.009_bb0335","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/jdv.17331","article-title":"Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: a 24-week prospective randomized placebo-controlled study","volume":"35","author":"Fontas","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0340","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1468-3083.2006.02132.x","article-title":"Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study","volume":"21","author":"Middelkamp-Hup","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0345","first-page":"815","article-title":"Utilization of our toolkit: a systematic review and meta-analysis of surgical therapies in vitiligo treatment","volume":"48","author":"McCrary","year":"2020","journal-title":"Meta-Analysis"},{"key":"10.1016\/j.molmed.2024.04.009_bb0350","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1111\/jdv.18829","article-title":"Meek micrografting, a novel surgical technique for the treatment of vitiligo and piebaldism: a case series","volume":"37","author":"Post","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venerol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0355","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15099","article-title":"Dermatoscopic assessment of treatment response in patients undergoing autologous non-cultured epidermal cell suspension for the treatment of stable vitiligo: a prospective study","volume":"34","author":"Dev","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.molmed.2024.04.009_bb0360","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/09546634.2020.1751038","article-title":"Value of silicone gel in prevention of cobblestoning following punch minigrafting in vitiligo","volume":"33","author":"Anbar","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.molmed.2024.04.009_bb0365","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/jocd.13312","article-title":"Noncultured epidermal suspensions obtained from partial-thickness epidermal cuts and suction blister roofs for vitiligo treatment: a prospective comparative study","volume":"19","author":"Anbar","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0370","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0375","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15969","article-title":"Simvastatin and non-segmental vitiligo: a new potential treatment option?","volume":"35","author":"Shaker","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.molmed.2024.04.009_bb0380","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.0800928105","article-title":"T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR","volume":"105","author":"Sauer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.molmed.2024.04.009_bb0385","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/ajd.13999","article-title":"Insulin-like growth factor 1: a new prime mover in the pathogenesis of vitiligo","volume":"64","author":"El-Komy","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0390","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2021.03.028","article-title":"Repigmentation in a patient with vitiligo on crisaborole 2% ointment","volume":"11","author":"Tam","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.molmed.2024.04.009_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105627","article-title":"Type 1 interferons: a target for immune-mediated inflammatory diseases (IMIDs)","volume":"91","author":"Mathian","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.molmed.2024.04.009_bb0400","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ijd.12392","article-title":"Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo","volume":"54","author":"Vaccaro","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0405","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1111\/ajd.13346","article-title":"Repigmentation of acrofacial vitiligo with subcutaneous tildrakizumab","volume":"61","author":"Jerjen","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0410","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/jm900210d","article-title":"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor","volume":"52","author":"Man","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2024.04.009_bb0415","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2024.04.009_bb0420","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/exer.1999.0718","article-title":"Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue","volume":"69","author":"Lindquist","year":"1999","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0425","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13148-021-01153-y","article-title":"Betamethasone administration during pregnancy is associated with placental epigenetic changes with implications for inflammation","volume":"13","author":"Czamara","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.molmed.2024.04.009_bb0430","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.molmed.2024.04.009_bb0435","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41422-021-00552-3","article-title":"Structural insights into ligand recognition and activation of the melanocortin-4 receptor","volume":"31","author":"Zhang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0440","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.4049\/jimmunol.161.6.2873","article-title":"Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents","volume":"161","author":"Manna","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0445","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jid.2020.11.034","article-title":"Development of hMC1R selective small agonists for sunless tanning and prevention of genotoxicity of UV in melanocytes","volume":"141","author":"Koikov","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0450","doi-asserted-by":"crossref","first-page":"13353","DOI":"10.3390\/ijms241713353","article-title":"The impact of metformin on tumor-infiltrated immune cells: preclinical and clinical studies","volume":"24","author":"Abdelmoneim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.04.009_bb0455","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun."},{"key":"10.1016\/j.molmed.2024.04.009_bb0460","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/jdv.19022","article-title":"The possible role of Wnt\/\u03b2-catenin signalling in vitiligo treatment","volume":"37","author":"Lin","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0465","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/jid.2013.235","article-title":"Wnt\/\u03b2-catenin and kit signaling sequentially regulate melanocyte stem cell differentiation in UVB-induced epidermal pigmentation","volume":"133","author":"Yamada","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0470","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0475","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2024.04.009_bb0480","article-title":"Compromised melanocyte survival due to decreased suppression of CD4(+) & CD8(+) resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients","volume":"33","author":"Shah","year":"2023","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.molmed.2024.04.009_bb0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-148X.2011.00898.x","article-title":"L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions","volume":"25","author":"Slominski","year":"2012","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.molmed.2024.04.009_bb0490","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000131485","article-title":"Autoimmune etiology of generalized vitiligo","volume":"10","author":"Le Poole","year":"2008","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.molmed.2024.04.009_bb0495","series-title":"Vitiligo","first-page":"285","article-title":"Immunity\/immunopathology","author":"Webb","year":"2019"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:04:47Z","timestamp":1726373087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1471491424000972"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.04.009","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo: advances in pathophysiology research and treatment development","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}